JP7403441B2 - 抗trem2抗体及びその使用方法 - Google Patents

抗trem2抗体及びその使用方法 Download PDF

Info

Publication number
JP7403441B2
JP7403441B2 JP2020515175A JP2020515175A JP7403441B2 JP 7403441 B2 JP7403441 B2 JP 7403441B2 JP 2020515175 A JP2020515175 A JP 2020515175A JP 2020515175 A JP2020515175 A JP 2020515175A JP 7403441 B2 JP7403441 B2 JP 7403441B2
Authority
JP
Japan
Prior art keywords
antibody
trem2
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534277A5 (cg-RX-API-DMAC7.html
JP2020534277A (ja
Inventor
ハン チェン
パオロ ギルバート ディ
ルイ ハオ
ジョセフ ダブリュ. リューコック
アリシア エー. ニュージェント
リシ ラキット
ジュ シー
リンカン シュクラ
レンゲリッチ ベティーナ ヴァン
イン チャン
ネイサン メルケ
アンキター シュリーヴァスタヴァ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2020534277A publication Critical patent/JP2020534277A/ja
Publication of JP2020534277A5 publication Critical patent/JP2020534277A5/ja
Priority to JP2023136384A priority Critical patent/JP2023163183A/ja
Application granted granted Critical
Publication of JP7403441B2 publication Critical patent/JP7403441B2/ja
Priority to JP2025113952A priority patent/JP2025133893A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020515175A 2017-09-14 2018-09-14 抗trem2抗体及びその使用方法 Active JP7403441B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023136384A JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法
JP2025113952A JP2025133893A (ja) 2017-09-14 2025-07-04 抗trem2抗体及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762558803P 2017-09-14 2017-09-14
US62/558,803 2017-09-14
US201762583379P 2017-11-08 2017-11-08
US62/583,379 2017-11-08
US201862621380P 2018-01-24 2018-01-24
US62/621,380 2018-01-24
PCT/US2018/051166 WO2019055841A1 (en) 2017-09-14 2018-09-14 ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023136384A Division JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2020534277A JP2020534277A (ja) 2020-11-26
JP2020534277A5 JP2020534277A5 (cg-RX-API-DMAC7.html) 2021-10-14
JP7403441B2 true JP7403441B2 (ja) 2023-12-22

Family

ID=63714159

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515175A Active JP7403441B2 (ja) 2017-09-14 2018-09-14 抗trem2抗体及びその使用方法
JP2023136384A Pending JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法
JP2025113952A Pending JP2025133893A (ja) 2017-09-14 2025-07-04 抗trem2抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023136384A Pending JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法
JP2025113952A Pending JP2025133893A (ja) 2017-09-14 2025-07-04 抗trem2抗体及びその使用方法

Country Status (6)

Country Link
US (1) US20200277373A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681909A1 (cg-RX-API-DMAC7.html)
JP (3) JP7403441B2 (cg-RX-API-DMAC7.html)
CN (1) CN111448212A (cg-RX-API-DMAC7.html)
CA (1) CA3075285A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019055841A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CA3120875A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
CN110511240B (zh) * 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
IL293018A (en) * 2019-11-22 2022-07-01 Lilly Co Eli trem2 antibodies and their uses
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
US20230265212A1 (en) * 2019-12-19 2023-08-24 Kevin S. EISENFRATS Compositions and methods for oocyte-specific contraception
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11124567B2 (en) * 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN115768794A (zh) 2020-02-24 2023-03-07 艾利妥 抗trem2抗体的使用方法
CA3172451A1 (en) 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
CN116323667A (zh) * 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CN114075284B (zh) * 2020-08-17 2023-11-17 上海元宋生物技术有限公司 Cd47结合分子及其用途
WO2022045865A1 (ko) * 2020-08-31 2022-03-03 (주)메디톡스 항-vegf 육량체 항체, 및 이를 포함하는 조성물
US20240102094A1 (en) * 2020-12-03 2024-03-28 Amgen Inc. Trem2 agonist biomarkers and methods of use thereof
CN112526143B (zh) * 2020-12-03 2021-08-03 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
IL308804A (en) * 2021-05-28 2024-01-01 Vigil Neuroscience Inc TREM2 agonistic biomarkers and methods of using them
CN115505041B (zh) * 2021-06-22 2026-05-05 北京免疫方舟医药科技有限公司 抗EphA2抗体及其应用
IL285416A (en) * 2021-08-05 2023-03-01 Yeda Res & Dev Antibodies for cancer treatment
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
WO2023039612A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023215697A1 (en) * 2022-05-05 2023-11-09 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
US20240262929A1 (en) * 2023-02-06 2024-08-08 Ibio, Inc. Anti-muc16 antibodies
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用
AU2024320793A1 (en) 2023-08-09 2026-03-12 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) * 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
CN117534569B (zh) * 2023-11-23 2026-03-13 复旦大学附属华山医院 S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途
CN118546252A (zh) * 2024-04-02 2024-08-27 上海宏成药业有限公司 抗trem2抗体及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503588A (ja) 2002-08-30 2006-02-02 バイオレクシス ファーマシューティカル コーポレイション 改変トランスフェリン融合タンパク質
JP2009544301A (ja) 2006-07-24 2009-12-17 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
JP2014030427A (ja) 2000-09-06 2014-02-20 Aventis Pharma Sa アミロイドーシスと関連する疾患のための方法及び組成物
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
JP2017523814A (ja) 2014-08-08 2017-08-24 アレクトル エルエルシー 抗trem2抗体及びその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014030427A (ja) 2000-09-06 2014-02-20 Aventis Pharma Sa アミロイドーシスと関連する疾患のための方法及び組成物
JP2006503588A (ja) 2002-08-30 2006-02-02 バイオレクシス ファーマシューティカル コーポレイション 改変トランスフェリン融合タンパク質
JP2009544301A (ja) 2006-07-24 2009-12-17 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
JP2017523814A (ja) 2014-08-08 2017-08-24 アレクトル エルエルシー 抗trem2抗体及びその使用方法
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Klein C. et al.,Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,MAbs,Vol. 4(6),2012年,pp. 653-663
Vidarsson G. et al.,IgG subclasses and allotypes: from structure to effector functions,Front Immunol,2014年,Vol. 5:520,pp. 1-17

Also Published As

Publication number Publication date
JP2025133893A (ja) 2025-09-11
WO2019055841A1 (en) 2019-03-21
JP2020534277A (ja) 2020-11-26
EP3681909A1 (en) 2020-07-22
US20200277373A1 (en) 2020-09-03
CA3075285A1 (en) 2019-03-21
CN111448212A (zh) 2020-07-24
JP2023163183A (ja) 2023-11-09

Similar Documents

Publication Publication Date Title
JP2023163183A (ja) 抗trem2抗体及びその使用方法
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
AU2021208482B2 (en) Anti-TREM2 antibodies and methods of use thereof
US11370832B2 (en) Anti-Tau antibodies and methods of use thereof
KR102695287B1 (ko) 항-phf-타우 항체 및 이의 용도
US20220119522A1 (en) Anti-trem2 antibodies and methods of use thereof
US11155627B2 (en) Anti-c-Met/anti-Ang2 bispecific antibody
US9808507B2 (en) Anti-c-Met/anti-Ang2 bispecific antibody
US20140302039A1 (en) Combination therapy using anti-c-met antibody and anti-ang-2 antibody
JP2021529796A (ja) 多特異性Wnt代替分子及びその使用
TW201827466A (zh) 抗-tau抗體及使用方法
JP7667075B2 (ja) アンタゴニスト
JP2024009870A (ja) 抗phf-タウ抗体及びその使用
WO2018237338A1 (en) Anti-alpha-synuclein antibodies and methods of use thereof
KR20180021875A (ko) 다중특이적 결합 단백질
KR20230034367A (ko) 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도
KR102106160B1 (ko) 항 Ang2 항체
KR20220092859A (ko) 항-cxcr2 항체 및 이의 용도
CN121057749A (zh) 抗cd3多特异性抗体和使用方法
EA046752B1 (ru) Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210906

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230825

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231212

R150 Certificate of patent or registration of utility model

Ref document number: 7403441

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150